Canadian evidence-based guidelines support the use of a cholinesterase inhibitor or memantine, or both drugs for the management of patients with severe Alzheimer's disease.
Ontario Public Drug Programs is asking pharmacists to be part of a pilot project for the next phase of MedsCheck, which is expected to begin in January 2009.